Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...